Table 1.
Clinical and biological characteristics of the 40 AML patients included in this study. Unless otherwise stated, the results are presented as the number of patients.
| Characteristics (n = 40) | |||
|---|---|---|---|
| Sex and age | Karyotype/Karyotype Abnormalities | ||
| Males/females | 21/19 | Normal | 20 |
| Age median (range) in years | 71 (18–87) | Favorable | 4 |
| Intermediate | 9 | ||
| Predisposition/previous disease | Adverse | 4 | |
| Previous chronic myeloid neoplasia | 1 | Not tested | 3 |
| Myelodysplastic syndrome | 8 | ||
| Relapsed AML | 3 | Flt3 abnormalities | |
| Chemotherapy related | 0 | ITD | 13 |
| Wild type | 19 | ||
| Morphology/FAB classification | Not tested | 8 | |
| M0/M1 | 17 | ||
| M2 | 8 | NPM1 abnormalities | |
| M4/M5 | 15 | Insertion | 13 |
| M6/M7 | 0 | Insertion + Flt3-ITD | 8 |
| Wild type | 20 | ||
| CD34 positive | 21 | Not tested | 7 |
Abbreviations: FAB, French-American-British; ITD, internal tandem duplication.